US4007265A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating tetanus toxin with a proteinase to produce an atoxic immunogenic product
Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1974-10-31
•
Granted: 1977-02-01
•
Expires: 1994-10-31
Abstract
Abstract An atoxic, immunogenic product obtained by treating tetanus toxin with a proteinase, a process for its manufacture and a tetanus vaccine containing as the essential ingredient said atoxic immunogenic product.
Inventors
- 👤 Torsten Bertil Helting
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 03:51
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/02; A61K39/08; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
42 words
The method of making an atoxic immunogenic product, adaptable to injection, which consists essentially of treating tetanus toxin with a peptide-peptido-hydrolase at a pH between 5 and 10 and not to cause the irreversible denaturation of the protein body of tetanus toxin.
Claim 2
Independent Claim
42 words
The method of making an atoxic immunogenic product, adaptable to injection, which consists essentially of treating tetanus toxin with a peptide-peptido-hydrolase at a pH between 5 and 10 and not to cause the irreversible denaturation of the protein body of tetanus toxin.
Claim 3
Dependent Claim
27 words
The method as in claim 1 wherein said product is purified by molecular sieve chromatography to isolate that fraction thereof having molecular weights between 20,000 and 60,000.
Claim 4
Dependent Claim
58 words
The method as in claim 1 wherein said product is treated, at a protein concentration of about 1 mg or less per ml, with 0.015 to 0.3 mole of an aliphatic mono- or di-aldehyde having 1 to 6 carbon atoms for 14 to 28 days at 20° C. to 37° C. at a pH of 6.0 to 8.5.
Claim 5
Dependent Claim
11 words
The method as in claim 3 wherein said aldehyde is formaldehyde.
Claim 6
Dependent Claim
27 words
The method as in claim 1 wherein said peptide-peptido-hydrolase is a member selected from the group consisting of papain, trypsin, bacterial proteinase from Bacillus subtilis, or pronase.
Claim 7
Dependent Claim
22 words
The method as in claim 1 wherein tetanus toxin is treated with 0.5 to 2 U of papain per milligram of toxin.
Claim 8
Dependent Claim
23 words
The method as in claim 1 wherein said tetanus toxin is treated with papain at a temperature of 40° C. to 60° C.
Claim 9
Dependent Claim
21 words
The method as in claim 1 wherein said tetanus toxin is treated with papain at a pH of 5 to 8.
Claim 10
Dependent Claim
23 words
The method as in claim 1 wherein said tetanus toxin is treated with papain in the presence of a compound containing sulfhydryl groups.
Claim 11
Dependent Claim
14 words
An atoxic immunogenic product, adaptable to injection, prepared by the method of claim 1.
Claim 12
Dependent Claim
14 words
An atoxic immunogenic product, adaptable to injection, prepared by the method of claim 3.
Claim 13
Dependent Claim
15 words
A tetanus vaccine comprising the atoxic immunogenic product of claim 10 as the effective ingredient.
Claim 14
Dependent Claim
15 words
A tetanus vaccine comprising the atoxic immunogenic product of claim 11 as the effective ingredient.
References Cited (Backward Citations)
US3542920A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-02-01 | 1980-08-02 | 1981-02-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-02-01 | 1984-08-02 | 1985-02-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-02-01 | 1988-08-02 | 1989-02-01 | $7700.00 | Window Closed / Lapsed |